Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Cybin Inc
(NY:
CYBN
)
0.3625
-0.0113 (-3.02%)
Official Closing Price
Updated: 8:00 PM EDT, May 10, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Cybin Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), Chopra Foundation Partner in Efforts to Support Progress Toward Psychedelic-Based Therapeutics
March 07, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Teams with Chopra Foundation to Foster Psychedelics Awareness
March 03, 2022
Via
Investor Brand Network
Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Teams Up with Chopra Foundation to Foster Psychedelics Therapy Awareness
March 02, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Oppenheimer Annual Healthcare Conference
March 02, 2022
Via
Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
March 02, 2022
Via
Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
March 02, 2022
Via
Investor Brand Network
Psychedelic Therapies Offer Hope for Mental Health
March 02, 2022
NetworkNewsWire Editorial Coverage New York, NY – March 2, 2022 – Neural plasticity is instrumental in brain health, and the importance of neuroplasticity can’t be overstated. Indeed, the inability of...
Via
FinancialNewsMedia
Cybin’s (NYSE American: CYBN) (NEO: CYBN) Study to Potentially Open New Frontiers in Psychedelics
February 28, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Feasibility Study to Potentially Open New Frontiers of Understanding Psychedelics
February 25, 2022
Via
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Reports Adelia Milestone
February 22, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Reports Achievement of Additional Adelia Milestone
February 18, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
February 18, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) CEO to Participate in Fireside Chat at Aegis Virtual Conference
February 16, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN), Chopra Foundation Team to Advance Psychedelics in Mental Health
February 16, 2022
Via
Investor Brand Network
Cybin to Participate in Aegis Virtual Conference on February 24, 2022
February 15, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN), The Chopra Foundation Partner to Uncover Potential of Psychedelic Therapies in Mental Health
February 15, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
February 15, 2022
Via
Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Working on Turning Psychedelics-to-Therapeutics(TM) Vision into Reality
February 14, 2022
Via
Investor Brand Network
Cybin (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound
February 10, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
February 10, 2022
From
Cybin Inc.
Via
Business Wire
PsychedelicNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Granted US Patent Covering Lead Proprietary Compound for Treatment of Anxiety Disorders
February 09, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
February 09, 2022
From
Cybin Inc.
Via
Business Wire
Cybin (NYSE American: CYBN) (NEO: CYBN) Marks 2021 Accomplishments, Eyes ‘Transformative’ 2022
February 07, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marks Major Accomplishments in 2021, Eyes ‘Truly Transformative’ 2022
February 04, 2022
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Product Safety
Cybin’s (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Begins Enrollment This Year
February 01, 2022
Via
Investor Brand Network
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) IRB-Approved Study Could ‘Lead to New Frontiers,’ Begins Enrollment This Year
January 31, 2022
Via
Investor Brand Network
Cybin’s (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Position in Emerging Wellness Trend
January 28, 2022
Via
Investor Brand Network
Cybin Announces Additional Adelia Milestone Achievement
January 27, 2022
From
Cybin Inc.
Via
Business Wire
Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Vision Strengthens Company’s Position in Emerging Wellness Trend
January 27, 2022
Via
Investor Brand Network
Cybin (NYSE American: CYBN) (NEO: CYBN) Schedules Release of Q3 Results, Conference Call
January 27, 2022
Via
Investor Brand Network
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.